articleIssue #5 2016 – Digital edition20 October 2016 | By European Pharmaceutical ReviewIn this issue: Biosimilars, Informatics, Ingredients, PAT, HPLC, Microbiology, Product Showcase, Regulation, and much more...
articleProduct Showcase 201620 October 2016 | By European Pharmaceutical ReviewThis product showcase features articles from Charles River, Eppendorf Inc. and Eurofins Lancaster Laboratories...
articleIngredients In-Depth Focus 201620 October 2016 | By European Pharmaceutical ReviewIn this Ingredients In-Depth Focus: Excipient quality and supplier interchangeability; Interpreting ICH’s evolving residual solvents guideline; Q&A with Meggle...
articleHPLC In-Depth Focus 201620 October 2016 | By European Pharmaceutical ReviewIn this HPLC In-Depth Focus: Resolving natural compound complexity with multidimensional chromatography; The advantages of temperature elevations in HPLC...
articleBiosimilars: litigation outlook20 October 2016 | By Dr Dominic E. AdairIn the Foreword article contributed by Consultant David P. Elder in Issue 3, 2016 of European Pharmaceutical Review, entitled ‘Biosimilars: future prospects’, Dr Elder concluded that it is likely that biosimilars will become increasingly established in both Europe and the United States and that in addition to proteins and peptides,…
articleSecurity considerations for external research20 October 2016 | By Michael H. Elliott (Atrium Research & Consulting)Intellectual Property (IP) is the lifeblood of the pharmaceutical industry. Without it, there would not be much of a business. Growing research and development globalisation, externalisation, the expansion of electronic data management systems and the lack of consistent global IP enforcement is increasing the capacity of external and internal parties…
articleAt-line swabbing analysis as a process analytical tool20 October 2016 | By Adeyinka Aina and Chris Edlin, Pharmaceutical Manufacturing Technology CentreSwabbing is a technique commonly used during pharmaceutical cleaning protocols to ensure that the cleaning process meets both safety and regulatory requirements; this allows for the cleaning process to be subsequently verified and validated1-7.
articleManaging contamination risks in glove holes in barrier separation technology20 October 2016 | By Corinna Maier, James L. DrinkwaterThe manufacture of sterile medicinal and therapeutic products increasingly calls for aseptic processing using barrier separation technology comprising isolators and restricted access barrier systems (RABS) that have glove-sleeve systems.
articleUnderstanding today’s drug pricing environment20 October 2016 | By Andrew Butcher (Charles River Associates)In a healthcare world that experiences a plethora of high-cost new therapies coming to market in parallel with price increases for existing speciality drugs, pharmaceutical companies are having to move away from traditional pricing models that are largely based on demand and what the market will bear. At the same…
